e-Therapeutics plc Notice of AGM and Posting of Annual Report (0085Z)
11 May 2023 - 4:00PM
UK Regulatory
TIDMETX
RNS Number : 0085Z
e-Therapeutics plc
11 May 2023
e-therapeutics plc
("e-therapeutics" or the "Company")
Notice of Annual General Meeting and Posting of Annual Report
and Accounts
London, UK, 11 May 2023 - e-therapeutics plc (AIM: ETX; OTCQX;
ETXPF), a company integrating computational power and biological
data to discover life-transforming RNAi medicines, announces that
its Annual Report and Accounts for the year ended 31 January 2023,
which includes the notice of its 2023 Annual General Meeting
("AGM") have been posted to shareholders today and are available on
the Company's website at:
https://www.etherapeutics.co.uk/application/files/9516/8317/9500/ETX_Annual_Report_2023.pdf
The AGM will be held at 12:30p.m. on 18 July 2023 at 4 Kingdom
Street, Paddington, London, W2 6BD.
The right to attend and vote at the AGM is determined by
reference to the Company's register of members. Only a member
entered in the register of members as at close of business on 14
July 2023 (or, if the AGM is adjourned, in the register of members
as at the close of business on the date which is two business days
before the time of the adjourned AGM) is entitled to attend and
vote at the AGM.
Shareholders who wish to register their votes on the resolutions
to be put to the AGM should do so by completing and signing the
proxy form that accompanies the notice of the AGM (or appoint a
proxy electronically if their shares are held in CREST) in
accordance with the instructions printed on the proxy form.
Please complete and return the form of proxy in accordance with
the instructions printed thereon as soon as possible and, in any
event, so that it is received by the Company's registrar, Neville
Registrars Limited, Neville House, Steelpark Road, Halesowen, B62
8HD not later than 12:30p.m. on 14 July 2023 .
If you do not have a proxy form and believe that you should have
one, or if you have any additional queries on voting, please
contact Neville Registrars Limited.
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
Laura Roca-Alonso, COO/CBO 8888
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary HepNet(TM) platform enables the generation and
analysis of biological network models, providing a novel and
mechanistic approach to drug discovery. This approach explicitly
considers the true complexity of biology to make more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.
GalOmic (TM) , ETX's proprietary RNAi platform, enables the
targeted delivery to hepatocytes in the liver and the specific
silencing of novel disease-associated genes, identified by
HepNet(TM) . The focus on hepatocytes offers the opportunity to
tackle a wide variety of diseases. The liver is a highly
metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalOmic (TM) constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of
action.
The Company is progressing a pipeline of first-in-class
preclinical RNAi candidates across several high unmet medical needs
in cardiometabolic indications and targeting promising
hepatocyte-expressed targets with effects in other disease areas.
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. E-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAMMFTMTJBBMJ
(END) Dow Jones Newswires
May 11, 2023 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Oct 2024 to Nov 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Nov 2023 to Nov 2024
